ADMA in the 13F filings
Adma Biologics Inc · CUSIP 000899104
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 14 Aug 2024
- latest of these filings; the earliest 9 Aug 2024
- Managers listing it
- 6
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 4 listed it in both
- Shares listed
- 20,109,399
- combined, among listed positions
- Reported value
- $225m
- combined, at the quarter end
Among the 94 comparable managers: 5 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing ADMA in Q2 2024
6 of 6 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| D. E. Shaw & Co. | 6,824,517 | $76m | 0.07% | Added | n.a. | 14 Aug 2024 (the filing on sec.gov) |
| Two Sigma Advisers LP | 4,654,600 | $52m | 0.12% | Added | +1,195,000 | 14 Aug 2024 (the filing on sec.gov) |
| Two Sigma Investments LP | 4,027,600 | $45m | 0.10% | Added | +181,642 | 14 Aug 2024 (the filing on sec.gov) |
| Renaissance Technologies LLC | 2,582,135 | $29m | under 0.1% | Added | n.a. | 9 Aug 2024 (the filing on sec.gov) |
| Voloridge Investment Management LLC | 1,813,820 | $20m | 0.08% | Added | +135,263 | 14 Aug 2024 (the filing on sec.gov) |
| Caxton Associates LLP | 206,727 | $2.3m | 0.08% | Trimmed | -182,464 | 14 Aug 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Two Sigma Advisers LPexisting position · 4,654,600 shares now+1,195,000
- Two Sigma Investments LPexisting position · 4,027,600 shares now+181,642
- Voloridge Investment Management LLCexisting position · 1,813,820 shares now+135,263
Reductions
- Caxton Associates LLPexisting position · 206,727 shares now-182,464
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2019 | 1 | $8.4m | n.a. | n.a. |
| Q3 2019 | 1 | $7.0m | n.a. | n.a. |
| Q4 2019 | 1 | $5.0m | n.a. | n.a. |
| Q1 2020 | 1 | $2.1m | n.a. | n.a. |
| Q2 2020 | 2 | $2.4m | n.a. | n.a. |
| Q3 2020 | 2 | $6.2m | n.a. | n.a. |
| Q1 2022 | 1 | $4.2m | n.a. | n.a. |
| Q2 2022 | 1 | $4.3m | n.a. | n.a. |
| Q3 2022 | 1 | $4.9m | n.a. | n.a. |
| Q4 2022 | 2 | $7.4m | n.a. | n.a. |
| Q1 2023 | 1 | $678k | n.a. | n.a. |
| Q2 2023 | 2 | $11m | n.a. | n.a. |
| Q3 2023 | 1 | $11m | n.a. | n.a. |
| Q4 2023 | 2 | $13m | 1 | 1 |
| Q1 2024 | 4 | $62m | 4 | 0 |
| Q2 2024 | 6 | $225m | 5 | 1 |
| Q3 2024 | 8 | $378m | 4 | 4 |
| Q4 2024 | 7 | $209m | 3 | 3 |
| Q1 2025 | 7 | $187m | 3 | 4 |
| Q2 2025 | 6 | $88m | 3 | 2 |
| Q3 2025 | 4 | $221m | 2 | 3 |
| Q4 2025 | 8 | $464m | 16 | 17 |
| Q1 2026 | 3 | $106m | 22 | 9 |
| Q2 2026 | 1 | $73m | 10 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ADMA and GILD →ADMA and AMGN →ADMA and ARGX →Choose a stock to compare with ADMA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ADMA, latest filings →Back to the 13F Explorer →